Cargando…

Real-world outcomes among patients with HER2+ metastatic breast cancer with brain metastases

BACKGROUND: Among patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC), incidence of brain metastases (BMs) is relatively high and increasing. Despite the high unmet need for patients with HER2+ MBC and BMs, real-world data on treatment patterns and...

Descripción completa

Detalles Bibliográficos
Autores principales:	DeBusk, Kendra, Ike, Chiemeka, Lindegger, Nicolas, Schwartz, Naomi, Surinach, Andy, Liu, Yutong, Forero-Torres, Andres
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373006/ https://www.ncbi.nlm.nih.gov/pubmed/35621719 http://dx.doi.org/10.18553/jmcp.2022.28.6.657

Ejemplares similares

Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer
por: Kaufman, Peter A., et al.
Publicado: (2023)

Real‐world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma
por: Yu, Kenneth H., et al.
Publicado: (2021)

Real-world Impact of Age at Diagnosis on Treatment Patterns and Survival Outcomes of Patients with Metastatic Pancreatic Ductal Adenocarcinoma
por: Elias, Rawad, et al.
Publicado: (2022)

The Association of Real-World CA 19-9 Level Monitoring Patterns and Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma
por: George, Ben, et al.
Publicado: (2021)

Comparing real-world evidence among patients with metastatic pancreatic ductal adenocarcinoma treated with liposomal irinotecan
por: Koeller, Jim, et al.
Publicado: (2020)

Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States
por: Barzi, Afsaneh, et al.
Publicado: (2020)

Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study
por: Sanglier, Thibaut, et al.
Publicado: (2023)

Qualitative and quantitative validation of the FACIT-fatigue scale in iron deficiency anemia
por: Acaster, Sarah, et al.
Publicado: (2015)

Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database
por: Pal, Sumanta, et al.
Publicado: (2019)

Real-world treatment in patients with HER2+ metastatic breast cancer: Treatment decisions in HER2+ mBC
por: Colomer, R., et al.
Publicado: (2017)

P02.194. Newly developed functional medicine program in diabetes: impact on clinical and patient reported outcomes - functional medicine and quality of life
por: Franic, D, et al.
Publicado: (2012)

Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study
por: Zhang, Qiongwen, et al.
Publicado: (2023)

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2022)

Real-world data of HER2-low metastatic breast cancer: A population based cohort study
por: Holthuis, Emily I., et al.
Publicado: (2022)

Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program
por: Le Du, Fanny, et al.
Publicado: (2023)

Non–Small Cell Lung Cancer Symptom Assessment Questionnaire: Psychometric Performance and Regulatory Qualification of a Novel Patient-Reported Symptom Measure
por: Bushnell, Donald M., et al.
Publicado: (2021)

Heterozygous deficiency of δ-catenin impairs pathological angiogenesis
por: DeBusk, Laura M., et al.
Publicado: (2010)

Heterozygous deficiency of δ-catenin impairs pathological angiogenesis
por: DeBusk, Laura M., et al.
Publicado: (2010)

Heterozygous deficiency of δ-catenin impairs pathological angiogenesis
por: DeBusk, Laura M., et al.
Publicado: (2010)

Military-Type Workload and Footwear Alter Lower Extremity Muscle Activity during Unilateral Static Balance: Implications for Tactical Athletic Footwear Design
por: Hill, Christopher M., et al.
Publicado: (2020)

Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer
por: Gómez-Ulloa, David, et al.
Publicado: (2020)

Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study
por: Gui, Xinyu, et al.
Publicado: (2020)

Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2– patients with metastatic breast cancer
por: Li, Jingping, et al.
Publicado: (2021)

Multicentric real world evidence with palbociclib in hormone positive HER2 negative metastatic breast cancer in Indian population
por: Agrawal, Chaturbhuj, et al.
Publicado: (2021)

Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan
por: Nozawa, K., et al.
Publicado: (2023)

Bone Metastases Pattern in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: A Real-World Analysis in the SEER Database
por: Yang, Xiaojing, et al.
Publicado: (2020)

Peer-Assisted Learning in Undergraduate Medical Education for Resilience and Well-being
por: Snapp, Cathy, et al.
Publicado: (2022)

Effectiveness of second-line anti-HER2 treatment in HER2-positive metastatic breast cancer patients previously treated with trastuzumab: A real-world study
por: Zhao, Wei, et al.
Publicado: (2020)

Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
por: Sun, Ying, et al.
Publicado: (2021)

A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer
por: Shao, Yingbo, et al.
Publicado: (2022)

Remarkable NO oxidation on single supported platinum atoms
por: Narula, Chaitanya K., et al.
Publicado: (2014)

B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer
por: Steenbruggen, Tessa G., et al.
Publicado: (2023)

Comparing patient global impression of severity and patient global impression of change to evaluate test–retest reliability of depression, non-small cell lung cancer, and asthma measures
por: Eremenco, Sonya, et al.
Publicado: (2022)

Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
por: Lux, Michael P., et al.
Publicado: (2018)

Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States
por: Zanotti, Giovanni, et al.
Publicado: (2017)

A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience
por: Vici, Patrizia, et al.
Publicado: (2017)

Real-world Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis
por: Statler, Abby B., et al.
Publicado: (2019)

Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer
por: Bae, Soong June, et al.
Publicado: (2021)

Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database
por: Annonay, Mylène, et al.
Publicado: (2021)

Treatment with pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer: a multicenter real-world study
por: Hua, Yijia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pbeg9i2pmj2jb14gm0fmjsv0l6